Last week, Gabather published its 2020 year-end report, which shows that the company is ramping up its clinical development with GT-002. Going forward the company will focus on studying the effects of its top candidate on brain activity, which will be a key step in determining dosage of GT-002 to use in future patient studies. BioStock has spoken to CEO Michael-Robin Witt to find out more.
Read the full interview with Dr Michael-Robin Witt at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital.